<DOC>
	<DOC>NCT00946998</DOC>
	<brief_summary>This is a randomized double-blinded placebo-controlled trial to see if treatment with sertraline as compared with placebo tablets will improve depression symptoms in patients with chronic kidney disease who have not yet started dialysis or received a kidney transplant. The investigators will also investigate whether sertraline treatment will improve quality of life and whether it is safe to use in patients with kidney disease. The study subject will be randomly assigned to take either sertraline or a placebo tablet for 12 weeks.</brief_summary>
	<brief_title>Chronic Kidney Disease Antidepressant Sertraline Trial</brief_title>
	<detailed_description>This is a randomized double-blinded placebo-controlled trial of adults with predialysis stages 3-5 Chronic Kidney Disease and Major Depressive Episode. Subjects will be randomized in a double-blind fashion to placebo or sertraline (beginning at 50 mg/d and escalated by 50 mg increments every 2 weeks to a maximum of 200 mg/d) and followed for 12 weeks. The primary outcome is to investigate if treatment with sertraline, as compared with placebo, results in an improvement in depression symptom severity as measured by the Quick Inventory of Depressive Symptomatology Clinician Rated (QIDS-C-16) score. Secondary outcomes include whether sertraline, as compared with placebo, improves overall function and quality of life and whether it will result in more serious adverse events.</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Sertraline</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<criteria>Male or female adults aged greater than 21 years. Predialysis stages 3, 4 or 5 CKD. Current Major Depressive Episode. QIDC16 score of 11. Able to understand and sign informed consent. No healthcare power of attorney to sign informed consent. Unwilling or unable to participate. Kidney transplant recipient. Initiated on maintenance dialysis Significant hepatic dysfunction or liver enzyme abnormalities 3 times the upper limits of normal. Terminal chronic obstructive pulmonary disease or cancer. Recent history of active bleeding, such as gastrointestinal bleeding requiring hospitalization 3 months prior Current use of class I antiarrhythmic medications. Use of pimozide, MAO inhibitors, reserpine, guanethidine, cimetidine or methyldopa; tricyclic antidepressants, neuroleptics or anticonvulsants, excluding gabapentin Use of other serotonergic drugs or supplements such as triptans, tramadol, linezolid, tryptophan, and St. John's Wort. Ongoing use of antidepressants Past treatment failure on Sertraline Initiation of psychotherapy for depression in the 3 months prior to study entry Alcohol or substance abuse or dependence that requires acute detoxification at study entry Present or past psychosis or Bipolar I or II disorder Dementia or a MiniMental State Examination score of &lt;23 Suicidal ideation Pregnancy, lactation and women of childbearing potential not using adequate contraception</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Chronic Kidney Disease</keyword>
	<keyword>Depression</keyword>
	<keyword>Antidepressants</keyword>
	<keyword>randomized controlled trial</keyword>
	<keyword>treatment</keyword>
	<keyword>Sertraline</keyword>
</DOC>